SCHEMBL789726

SCHEMBL789726

Nc1ccc(Br)cc1CO

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
GLA P06280 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.44
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
SLC6A3 Q01959 1/20 0.43
MAPT P10636 4/20 0.40
POLB P06746 1/20 0.40
PLAU P00749 1/20 0.39
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPC1 O15118 1/20 0.36
CHEK1 O14757 1/20 0.35
MAPK1 P28482 2/20 0.35
LMNA P02545 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALOX15 P16050 2/20 0.35
TSHR P16473 1/20 0.34
GFER P55789 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29729453 1.00 KDM4E (0.45) KDM4EGLAPTGDR2SLC6A2SLC6A4
Bromide SCHEMBL7921725 0.98 KDM4E (0.44) KDM4EGLAPTGDR2SLC6A2SLC6A4
SCHEMBL6264119 0.83 KDM4E (0.42) KDM4EGLAPTGDR2SLC6A2SLC6A4
SCHEMBL754025 0.82 KDM4E (0.41) KDM4EGLAPTGDR2SLC6A2SLC6A4
Bromide SCHEMBL7930547 0.81 KDM4E (0.41) KDM4EGLAPTGDR2SLC6A2SLC6A4
SCHEMBL423154 0.79 CYP2A6 (0.46) KDM4EGLAMAPTPOLBPLAU
SCHEMBL795719 0.78 PTGDR2 (0.48) PTGDR2SLC6A2SLC6A4SLC6A3MAPT
SCHEMBL29417721 0.78 PTGDR2 (0.48) PTGDR2SLC6A2SLC6A4SLC6A3MAPT
Hydrochloric Acid SCHEMBL933206 0.77 CYP2A6 (0.44) KDM4EGLAMAPTPOLBPLAU
SCHEMBL19970560 0.77 KDM4E (0.41) KDM4EGLASLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 US disclosed
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof TORAY INDUSTRIES, INC. (JP) 2026-03-10 US disclosed
US-20260055108-A1 TRIAZINE COMPOUNDS AND USES THEREOF HUTCHMED LTD (CN) 2026-02-26 US disclosed
US-12528791-B2 Thyroid hormone receptor beta agonist compounds TERNS PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety CURIS INC (US) 2025-07-17 US disclosed
CN-119972172-A Heterogeneous organic polymer catalyst, preparation method thereof and method for synthesizing aldehyde or lactone compound 武汉光化学技术研究院 2025-05-13 CN disclosed
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 EP disclosed
EP-4545079-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS Toray Industries, Inc. (JP) 2025-04-30 EP disclosed
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 CN disclosed
CN-115960350-B Polymer, resin composition, and production method and application thereof 上海邃铸科技有限公司 2024-10-01 CN disclosed
US-6172061-B1 AIDS THERAPY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-01-09 US disclosed
US-6166006-A Anilide derivative, production and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-12-26 US disclosed
EP-1040103-A1 ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-10-04 EP disclosed
EP-1039899-A2 PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE Takeda Chemical Industries, Ltd. (JP) 2000-10-04 EP disclosed
WO-1999032100-A2 PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-07-01 WO disclosed
WO-1999032468-A1 ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-07-01 WO disclosed
WO-1999028290-A1 SYNTHESIS OF OLIGOARYLAMINES, AND USES AND REAGENTS RELATED THERETO MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1999-06-10 WO disclosed
US-5843972-A Heterocyclic β-adrenergic agonists PFIZER INC. (US) 1998-12-01 US disclosed
EP-0801060-A1 Heterocyclic Beta-3 Adrenergenic Agonists PFIZER INC. (US) 1997-10-15 EP disclosed
CN-85100796-A The preparation method of qualone derivative 1986-10-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AIFM2, GPX1, SOD1 KDM4E 2176/4885GLA 3389/4885PTGDR2 1797/4885
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety BAZ2A, BAZ2B, PI4KB KDM4E 868/4885GLA 2443/4885PTGDR2 3033/4885
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof AIFM2, GPX1, GPX4 KDM4E 1759/4885GLA 4600/4885PTGDR2 1217/4885
US-12528791-B2 Thyroid hormone receptor beta agonist compounds THRB, THRA, TSHR KDM4E 4744/4885GLA 2170/4885PTGDR2 418/4885
US-20260055108-A1 TRIAZINE COMPOUNDS AND USES THEREOF CBR1, CNR1, CBR3 KDM4E 3502/4885GLA 2906/4885PTGDR2 1169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.